DETAILED ACTION
This action is in reply to papers filed 5/26/2026. Claims 22-40 are pending and examined herein.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Examiner’s Note
All paragraph numbers throughout this office action, unless otherwise noted, are from the US PGPub of this application US20230357723A1, Published 11/9/2023.
Maintained Rejection(s)
The nonstatutory double patenting rejection of claims 32 and 38-40 as being unpatentable over claims 1-5 of U.S. Patent No. 11613732 is maintained. Applicant’s arguments will be addressed following maintained rejection.
Withdrawn Rejection(s)
The 112 (b) rejection of claims 22, 25 and 32 are withdrawn in view of amendments made to each of said claim.
The 112 (d) rejection of claims 29-30 and 34-35 are withdrawn in view of amendments made to the claims.
The 102 (a)(1) rejection of claims 22-23, 25, 29 and 37 as being anticipated by Steketee et al. (Proc Natl Acad Sci U S A. 2011 Nov 7;108(47):19042–19047) is withdrawn in view of amendments made to claim 22.
The 102 (a)(1) rejection of claims 33-34 as being anticipated by Li et al. (Biochim Biophys Acta. 2012 Sep;1817(9):1628-34.) is withdrawn in view of amendments made to claim 33.
The 103 (a) rejection of claim 24 as being obvious over Steketee et al. as applied to claims 22-23, 25, 29 and 37 above and Nilsang et al. (Biotechnol Prog. 2008 Sep-Oct;24(5):1122-31.) is withdrawn in view of the amendments to claim 22.
The 103 (a) rejection of claims 26-28 as being obvious over Steketee et al. as applied to claims 22-23, 25, 29 and 37 above and Richard et al. (Eur J Neurosci. 2005 Nov;22(9):2145-58) is withdrawn in view of the amendments to claim 22.
The 103 (a) rejection of claims 30-31 as being obvious over Steketee et al. as applied to claims 22-23, 25, 29 and 37 above and Das et al. (Biomaterials. 2004 Nov;25(25):5643-7.) is withdrawn in view of the amendments to claim 22.
The 103 (a) rejection of claims 33-36 as being obvious over Vukadinovic-Nikolic et al. (Tissue Eng Part A. 2014 Feb;20(3-4):799-809.), Thavandiran et al. (Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):E4698-707.) and Cao et al. (Cell Res. 2011 Dec 6;22(1):219–236.) is withdrawn in view of the amendments to claim 33.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Prior Art Rejection 1
Claim(s) 22-25, 28-29 and 37 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Gage et al. (PgPub US20160108361A1, Filed 4/17/2014).
Gage discloses a basal neuronal medium, BrainPhys. Regarding claim 22, Gage discloses BrainPhys comprises calcium chloride, magnesium sulfate, sodium bicarbonate, sodium phosphate, L-Alanyl-L-Glutamine (as in claim 24) and sodium pyruvate (see Table 2, Pg. 19). Gage discloses the concentration of L-Alanyl-L Glutamine is at a concentration of about 0.5 mM (as in claim 25) (Pg. 9, para. 96). Gage discloses the medium further comprises on or more supplemental agents selected from the group consisting of protein bovine serum albumin (BSA), insulin and ascorbic acid (Vit C) (as further in claim 22) (Pg. 8, para. 89). Gage discloses each supplemental agents is contained in the medium at a concentration of between about 0.01 and about 50 ug/mL (as in claim 28). Gage discloses the BrainPhys medium is serum-free (Pg. 9, para. 106), glutamic acid-free, glutamine-free, antibiotic-free, and HEPES-free (as in claim 23) (Table 2, Pg. 5, para. 55; Pg. 14, para. 143). Gage discloses using the medium for the maturation of neuronal cells (as in claim 29 and a sin claim 37) (Pg. 11, para.123).
Accordingly, Gage anticipates the claimed invention.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Prior Art Rejection 2
Claim 26 is rejected under 35 U.S.C. 103 as being unpatentable over Gage et al. (PgPub US20160108361A1, Filed 4/17/2014) as applied to claims and further in view of George et al. (PgPub US20150265652A1, Filed 3/20/2015).
The teachings of Gage et al. are relied upon as detailed above. And although Gage teaches ascorbic acid, Gage fails to teach the concentration of ascorbic acid is 200 ug/mL to about 700 ug/mL (as in claim 26).
George teaches methods for efficient production of midbrain dopaminergic (DA) neurons (Abstract). George teaches a maturation media comprising, inter alia, a Neurobasal media comprising B27 supplement, L-glutamine, 1 to 50 ng/ml BDNF, 1 to 50 ng/ml GDNF, 0.1 to 10 ng/ml TGFβ and 1 to 1,000 μM ascorbic acid (Pg.3 ,para. 26).
When taken with Gage’s objective of deriving a neuronal maturation medium, it would have been prima facie obvious to include ascorbic acid at about a 200 μM/ml to 700 μM/ml concentration in the BrainPhys medium of Gage et al. The skilled artisan would have found it prima facie obvious to do so because George teaches a maturation medium comprising 200 μM of albumin.
Thus, the modification would have been prima facie obvious.
Prior Art Rejection 2
Claim 27 is rejected under 35 U.S.C. 103 as being unpatentable over Gage et al. (PgPub US20160108361A1, Filed 4/17/2014) as applied to claims and further in view of Brewer, G. (PgPub US20080160006A1, Published 7/3/2008).
The teachings of Gage et al. are relied upon as detailed above. And although Gage teaches albumin, Gage fails to teach the concentration of albumin is 200 ug/mL to about 700 ug/mL (as in claim 27).
Brewer teaches an aqueous composition effective for improving neural cell viability in brain or spinal cord tissue in a human after brain or spinal cord injury or surgery or for improving neural cell viability of nervous system cells or tissue intended to be delivered into a brain, spinal cord, or nervous system of a human. Gage teaches the medium to do comprises about 5 to about 200 μM human albumin (as in claim 27) (Pg. 2, para. 12).
When taken with Gage’s objective of deriving a neuronal maturation medium, it would have been prima facie obvious to include albumin at about a 200 μM concentration in the BrainPhys medium of Gage et al. The skilled artisan would have found it prima facie obvious to do so because Brewer teaches a medium comprising 200 μM of albumin improvise neural cell viability.
Thus, the modification would have been prima facie obvious.
Prior Art Rejection 3
Claim(s) 30-31 are rejected under 35 U.S.C. 103 as being unpatentable over Gage et al. (PgPub US20160108361A1, Filed 4/17/2014) as applied to claims and further in view of Takeuchi et al. (Lab Chip (2011) 11 (13): 2268–2275.).
The teachings of Gage et al. are relied upon as detailed above. However, Gage fails to teach the cells are cardiomyocytes (as in claim 30).
Before the effective filing date of the claimed invention, Takeuchi et al. teach neuronal networks of in vivo models are too large and complex to be analyzed with clarity. One of the best approaches for understanding the modulation of cardiac function by the sympathetic nervous system is to analyze the function of a small cell network consisting of sympathetic neurons and cardiomyocytes (Abstract). Towards this end, Takeuchi teaches co-culturing neurons to cardiomyocytes in the same medium (Pg. 2270, Col. 2, para. 1).
With respect to claim 31, note that this limitation is being interpreted as a product-by-process limitation. The courts have consistently held that "Even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." In re Thorpe, 227 USPQ 964, 966 (Fed. Cir. 1985). In this regard, absent evidence to the contrary the cardiomyocytes of Takeuchi are reasonably considered to the same or obvious over the iPSC derived cardiomyocyte of claim 31.
When taken with the teachings of Takeuchi et al., one of ordinary skill in the art would have found it prima facie obvious to culture cardiomyocytes in the BrainPhys medium of Gage et al. The skilled artisan would have found it prima facie obvious to do in order to elucidate the modulation of cardiac function by the sympathetic nervous system using the in vitro system of sympathetic neurons and cardiomyocytes. The skilled artisan would have been sufficiently motivated to do so because Gage et al. explicitly teaches their medium aided in the maturation of neuronal cells. Thus, the modification would have been prima facie obvious.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 32-36 and 38-40 remain rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 of U.S. Patent No. 11613732 in view of Gage et al. (PgPub US20160108361A1, Filed 4/17/2014). Although the claims at issue are not identical, they are not patentably distinct from each other because of the following:
Instant claims are drawn a cell recovery medium comprising: the cell preservation medium of claim 22, Ml99, DMEM, glucose or other sugar based energy source, glutamine or an analog thereof, and one or more of ascorbic acid, albumin, or insulin, wherein the cell recovery medium has about 45% to about 55% cell preservation medium, wherein the cell recovery medium has about 10% to about 15% Ml99 and about 35% to about 40% DMEM.
For completeness, claim 22 is drawn to a cell medium comprising: cell preservation medium that comprises a cell hibernation medium and L-glutamine or an analog thereof, and ascorbic acid, albumin, insulin and the hibernation medium comprises calcium, magnesium, sodium phosphate, sodium bicarbonate and sodium pyruvate. Claims 33-36 depend from claim 32. Claim 38 is drawn to a method of culturing using the medium of claim 32. Claims 39-40 depend on claim 38.
Claim 1 of U.S. Patent ‘732 is drawn to a cell recovery medium comprising: M199, DMEM, glucose or other sugar based energy source, and cell preservation medium, wherein the cell recovery medium has about 45% to about 55% cell preservation medium, wherein the cell recovery medium has about 10% to about 15% M199 and about 35% to about 40% DMEM, wherein the cell preservation medium comprises cell hibernation medium, 0.5 mM to 4 mM L-glutamine or L-alanyl-L-glutamine dipeptide, ascorbic acid, albumin, and insulin, wherein the ascorbic acid is 100 μg/mL to 300 μg/mL, the albumin is 200 μg/mL to 700 μg/mL, and the insulin is 1 μg/mL to 20 μg/ml.
The difference between instant claims and the claims of the patent lie in the fact that instant claims define the cell hibernation medium to comprise calcium, magnesium, sodium phosphate, sodium bicarbonate and sodium pyruvate. However, such would have been prima facie obvious in view of Gage who teaches BrainPhys comprises calcium chloride, magnesium sulfate, sodium bicarbonate, sodium phosphate, and sodium pyruvate (see Table 2, Pg. 19). Gage teaches BrainPhys mimics the human brain physiological environment (Pg. 11, para. 123+) ~ this teaching is reasonably considered to teach a maintenance/hibernation medium.
Thus, it would have been prima facie obvious to substitute the generic hibernation medium of U.S. Patent ‘732 for the hibernation medium of Gage because Gage teaches such a medium mimics the human brain physiological environment.
Authorization to Initiate Electronic Communications
The examiner may not initiate communications via electronic mail unless and until applicants authorize such communications in writing within the official record of the patent application. See M.P.E.P. § 502.03, part II. If not already provided, Applicants may wish to consider supplying such written authorization in response to this Office action, as negotiations toward allowability are more easily conducted via e-mail than by facsimile transmission (the PTO's default electronic-communication method). A sample authorization is available at § 502.03, part II.
Conclusion
No claim is allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to TITILAYO MOLOYE whose telephone number is (571)270-1094. The examiner can normally be reached Working Hours: 5:30 a.m-3:00 p.m. M-F. Off first Friday of biweek.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached on 571- 272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
Authorization to Initiate Electronic Communications
The examiner may not initiate communications via electronic mail unless and until applicants authorize such communications in writing within the official record of the patent application. See M.P.E.P. § 502.03, part II. If not already provided, Applicants may wish to consider supplying such written authorization in response to this Office action, as negotiations toward allowability are more easily conducted via e-mail than by facsimile transmission (the PTO's default electronic-communication method). A sample authorization is available at § 502.03, part II.
Conclusion
No claim is allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to TITILAYO MOLOYE whose telephone number is (571)270-1094. The examiner can normally be reached Working Hours: 5:30 a.m-3:00 p.m. M-F. Off first Friday of biweek.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached on 571- 272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/TITILAYO MOLOYE/Primary Examiner, Art Unit 1632